USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
HAWAII BIOTECH, INC.
Address:
99-193 AIEA HEIGHTS DRIVE, SUITE 200
AIEA, HI
Phone:
N/A
URL:
N/A
EIN:
990214983
DUNS:
113226823
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $10,809,780.00 78
SBIR Phase II $17,574,697.00 19

Award List:

DEVELOPMENT OF PALYTOXIN IMMUNOTOXINS PHASE I

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$71,800.00
Agency:
HHS
Principal Investigator:
Douglas C. Vann, Ph.d.
Abstract:
N/a

DEVELOPMENT OF PALYTOXIN IMMUNOTOXINS PHASE I

Award Year / Program / Phase:
1984 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Douglas C. Vann, Ph.d.
Abstract:
The objective of this project is to establish methods for conjugating the potent marine toxin, palytoxin to antibodies in such a way that specific cytotoxicity of target cells is possible. the product, immunopalytoxin (ipt), should be easily prepared, have high specific cytotoxic activity and be… More

RAPID DETECTION OF CARBOFURAN IN FOOD AND ENVIRONMENTAL SAMPLES.

Award Year / Program / Phase:
1984 / SBIR / Phase I
Award Amount:
$42,000.00
Agency:
USDA
Principal Investigator:
Douglas C. Vann
Abstract:
N/a

RAPID DETECTION OF CARBOFURAN IN FOOD AND ENVIRONMENTAL SAMPLES.

Award Year / Program / Phase:
1985 / SBIR / Phase II
Award Amount:
$200,000.00
Agency:
USDA
Principal Investigator:
Douglas C. Vann
Abstract:
We propose to develop an immunoassay for the pesticide, carbofuran. phase i will consist of synthesizing suitable haptens, conjugating these haptens to an immunogenic carrier, preparing and screening rabbit antisera, and conducting preliminary competitive elisa tests to demonstrate the feasibility… More

THE OBJECTIVE OF THIS PROJECT IS TO USE IMMUNOLOGICAL METHODS TO PURIFY AND CHARACTERIZE THE 50 KDA ANOREXIGEN ISOLATED PREVIOUSLY IN LOW YIELDS USING CONVENTIONAL PROCEDURES.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Douglas c. vann , PRINCIPAL INVESTIGATOR
Abstract:
The objective of this project is to use immunological methods to purify and characterize the 50 kda anorexigen isolated previously in low yields using conventional procedures. a small amount of the purified anorexigen is presently available and will be used to generate a set of monoclonal… More

DENGUE VACCINE DEVELOPMENT

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Morton Mandel
Abstract:
N/a

TETRODOTOXIN IMMUNOASSAYS

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Navzer D Sachinvala
Abstract:
N/a

IMMUNOASSAYS FOR SAXITOXINS

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$44,000.00
Agency:
HHS
Principal Investigator:
Navzer d. sachinvala, ph. , PRINCIPAL INVESTIGATOR
Abstract:
The saxitoxins are neurotoxins and are among the most potent nonprotein toxins known. several thousand cases of paralytic shellfish poisoning occur worldwide each year, with a case-fatality rate approaching 10 percent. since there is no antidote for such poisoning, avoidance of contaminated material… More

DENGUE VACCINE DEVELOPMENT

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$553,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Morton Mandel
Abstract:
The ultimate objective of this project is the production of a dengue vaccine. the four dengue viruses (serotypes) as a group are by far the most important viruses transmitted to man by arthropods and in terms of global morbidity are responsible for several hundred thousand to several million cases… More

TETRODOTOXIN IMMUNOASSAYS

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$509,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Navzer D Sachinvala
Abstract:
Tetrodotoxin is a highly potent low molecular weight neurotoxin found in some species of pufferfish and a few other widely divergent organisms. currently, tetrodotoxin is measured by mouse bioassay or with sophisticated chromatographic methods. a simple, specific, easy to use assay method for… More

IMMUNOASSAY FOR AVAROL

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The overall goal of this project is to develop immunoassays capable of detecting avarol and avarone at the nanogram level in biological samples. avarol is a marine natural product with potent anti-tumor and anti-aids activity. thiscompound is undergoing evaluation as an anti-aids drug and an… More

IMMUMOASSAYS FOR DIDEMNINS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The overall goal of this project is to develop immunoassays capable of detecting didemnins at the nanogram level. didemnin b is the most potent antitumor, antiviral, and cytotoxic member of a family of five cyclic depsipeptides isolated from marine tunicates. this compound is currently in clinical… More

ORGANIC PHASE IMMUNOCHEMISTRY

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
NSF
Principal Investigator:
Paul G Grothaus , Principal Investigator
Abstract:
Immunochemical techniques have many diverse applications. however, they are restricted to use only in aqueous media. economical techniques for direct organic phase analysis and immunoaffinity isolation would significantly broaden the usefulness of antibody-based technology. the purpose of this… More

HETEROLOGOUS PROTEIN EXPRESSION IN NEUROSPORA

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
NSF
Principal Investigator:
John Marshall Ivy , Principal Investigator
Abstract:
The proposed research will investigate the ability of neurospora crassa to express and secrete biologically-activemammalian proteins. the ability to genetically engineer bacteria and yeasts for these tasks is well documented. however, recombinant products from these organisms often require costly… More

PRODUCTION OF DENQUE 2 ENVELOP PROTEIN IN THE YEAST SACCHAROMYCES CEREVISIAE

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$77,775.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Dr John M Ivy
Abstract:
N/a

EXPRESSION OF DENGUE 3 ENVELOPE AND NONSTRUCTURAL 1 GLYCOPROTEINS IN THE FUNGUS NEUROSPORA CRASSA

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$67,723.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Dr John M Ivy
Abstract:
The four serotypes of dengue viruses are a leading cause of morbidity throughout the tropics and subtropics. for the development of diagnostics for and subunit vaccines against dengue virus, a reliable and inexpensive source of dengue proteins is needed. the expression of recombinant proteins in… More

CLONING AND EXPRESSION OF RECOMBINANT HTLV-II ENVELOPE PROTEIN IN E. COLI

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Nichol Dolby
Abstract:
Human t-lymphotropic virus type ii (htlv-ii) is a human retrovirus related to, but distinct from, other retrovirusesthat are identified causative agents of disease. little is known about htlv-ii prevalence in the population or its disease associations because the study of htlv-ii has lagged, in part… More

IMMUNOASSAYS FOR TAXOL

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$48,659.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
N/a

PRODUCTION OF DENQUE 2 ENVELOP PROTEIN IN THE YEAST SACCHAROMYCES CEREVISIAE

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$571,526.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Dr John M Ivy
Abstract:
The four serotypes of dengue viruses are a leading cause of morbidity throughout the tropics and subtropics. for use in diagnostics and in subunit vaccines against dengue, a reliable and inexpensive source of dengue antigens is required. for these purposes, expression of recombinant antigens in… More

IMMUNOASSAYS FOR TAXOL

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$470,642.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
Taxol is a promising new anticancer drug, isolated from the bark of the western yew (taxus brevefolia), and is currentlyin phase ii clinical trials. development of this drug is impeded by a supply shortage. identification of new taxol sources is hampered by the lack of suitable assays for detecting… More

BISPECIFIC ANTIBODY FOR DIRECTED DELIVERY OF PALYTOXIN

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Bignami, Gary S , Principal Investigator
Abstract:
Considerable interest has been focussed on the production and characterization of therapeutic immunoconjugates. such hybrid molecules usually consist of a monoclonal antibody with covalently attached toxin, drug, or radioisotope. some of these agents have been shown to be clinically useful for… More

COFFEE ALPHA-GALACTOSIDASE CDNA CLONING FOR BLOOD PROCESSING

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ivy, John M , Principal Investigator
Abstract:
It has been demonstrated that alpha-galactosidase and alpha-n-acetyl galactosaminidase have the ability to enzymatically convert type b and a human erythrocytes, respectively, to serotypically type o erythrocytes. this ability would obviate the need for typing or crossmatching, would simplify… More

UREASE-LINED IMMUNOASSAY REAGENT STABILITY STUDIES

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$53,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Dr T J G Raybould , Principal Investigator
Abstract:
N/a

MINIATURIZED FT-IR SENSOR FOR INFRARED MEASUREMENTS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$53,228.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
John marshall ivy , PRINCIPAL INVESTIGATOR
Abstract:
N/a

PALYTOXIN PRODRUG ACTIVATION BY ANTIBODY-LINKED ENZYME

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Bignami, Gary S , Principal Investigator
Abstract:
N/a

PALYTOXIN PRODRUG ACTIVATION BY ANTIBODY-LINKED ENZYME

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$459,212.00
Agency:
HHS
Principal Investigator:
Bignami, Gary S , Principal Investigator
Abstract:
Palytoxin is an extremely cytotoxic low molecular weight natural product isolated from soft corals of the genus, palythoa. n-acylated derivatives of palytoxin have been reported to be up to 100-fold less cytotoxic than the unmodified toxin. palytoxin n-acyl derivatives which can be converted to the… More

UREASE-LINED IMMUNOASSAY REAGENT STABILITY STUDIES

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$901,147.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Dr T J G Raybould , Principal Investigator
Abstract:
Urease offers distinct advantages over other enzymes for preparation of conjugates used in enzyme-linked immuno-sorbent assay systems. molecular devices corporation (menlo park, ca) has capitalized on these advantages in their threshold system. this impressive system utilizes avidin-biotin to… More

NEUROSPORA SECRETION EXPRESSION VECTOR DEVELOPMENT

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
NSF
Principal Investigator:
Eileen T. Nakano, Ph.d.
Abstract:
Production of recombinant products of pharmaceutical and industrial importance in a variety of microorganisms has yielded a wide variety of biologically active proteins. fungi offer the advantage of reduced culturing and downstream processing costs because they are capable of secreting prodigious… More

FUNGAL EXPRESSION OF DENGUE PROTEINS FOR VACCINES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
John M Ivy
Abstract:
Dengue viruses are a leading cause of morbidity throughout the tropics and subtropics. attempts to develop live attenuated dengue vaccines analogous to the yellow fever vacine have been unsuccessful. in an effort to contrubite to the development of a recombinant subunit dengue vaccine, we will… More

CATALYTIC ANTIBODIES FOR PALYTOXIN PRODRUG ACTIVATION

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
Transition state analog haptens will be prepared for the elicitation of antibodies which can catalyze the conversion of palytoxin prodrugs to palytoxin.

POLIO/DENGUE CHIMERAE FOR DENGUE VACCINE DEVELOPMENT

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Eileen T Nakano
Abstract:
We will construct hybrid polio/dengue virus genomes in order to develop a vaccine for dengue virus. in the chimeric genomes, one of two dengue virus envelope gene fragments will replace segment of the polio virus structural protein genes. such chimerae would have the ability to replicate in the gut… More

BISPECIFIC ANTIBODY FOR DIRECTED DELIVERY OF TAXOL

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary S Bignami
Abstract:
We will achieve the selective delivery of cytotoxic agents through the use of bispecific antibodies. taxol is a promising new anticancer agent isolated in low yield from the bark of the pacific yew tree, taxus brevifolia. the applicant will prepare a thioether-linked bispecific antibody with dial… More

ORGANIC PHASE IMMUNOASSASY FOR CHLORINATED DIBENZODIOXINS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary S Bignami
Abstract:
High affinity antigen-antibody binding is essentially anhydrous hydrophobic organic solvents has been demonstrated in our laboratory. using an estradiol-antiestradiol system, a prototype organic phase radioimmunoassay (opria) has been developed which detects 200 pg/ml or estradiol in a hexane medium… More

SYNTHESIS OF A PALYTOXIN-CEPHALOSPORIN PRODRUG

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Sean O'malley
Abstract:
A palytoxin produrg derivative will be prepared. this compound will be tested for its differential cytotoxicity compared to palytoxin; and for its ability to be enzymatically activated.

TAXOL PURIFICATION BY MONOCLONAL ANTIBODY IMMUNOADSORBENTS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
N/a

MINIATURIZED FT-IR SENSOR FOR INFRARED MEASUREMENTS

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$629,133.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
John marshall ivy , PRINCIPAL INVESTIGATOR
Abstract:
N/a

IMMUNOASSAYS FOR BRYOSTATINS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
N/a

TAXOL PURIFICATION BY MONOCLONAL ANTIBODY IMMUNOADSORBENTS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
This phase i project is designed to test the feasibility of purifying taxol by immunoaffinity chromatography. the use of this technique for purification of a low molecular weight compound with low aqueous solubility has not been reported to date. taxol-specific monoclonal antibodies will be selected… More

Synthesis of a Taxol-Cehalosporin Prodrug

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Sean O'Malley
Abstract:
A Taxol prodrug derivative will be prepared. This compound will be tested for its differential cytotoxicity compared to Taxol and for its ability to be enzymatically activated. The cytotoxicity of the prodrug in combination with a monoclonal-antibody enzyme conjugate in the presence of targeted and… More

CLONING AND STUDIES OF NEUROSPORA ALKALINE PROTEASE

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
NSF
Principal Investigator:
John Marshall Ivy
Abstract:
The development of microbial systems for expression of heterologous proteins has enabled the isolation of greater amounts of source proteins, often in greater purity than is posible from the original source. proteins so expressed have applications ranging from industrial use, through protein… More

Light-Regulated Heterologous Expression in Neurospora

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
John M. Ivy
Abstract:
Regulation of gene expression is critical for cellular and organismal development, and it often plays an important role in expression of heterologous recombinant proteins. Toward development of regulated expression vectors for filamentous fungi that will minimize materials cost and manipulation of… More

Expression of Single-chain FV in Neurospora Crassa

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Eileen T. Nakano
Abstract:
The filamentous fungi, owing to their ability to secrete high levels of proteins, are attractive organisms for the expression and secretion of heterologous proteins of commercial and medical value. Secretion is a key element in their attraction; secretion provides the opportunity for complex… More

DEVELOPMENT OF POLYCLONAL SERA AND MONOCLONAL HYBRIDOMAS TO WILD TYPE MEASLES VIRUS ANTIGENS

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

IMMUNOASSAYS FOR BRYOSTATINS

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$483,000.00
Agency:
HHS
Principal Investigator:
Paul G Grothaus
Abstract:
The overall goals of this project are to develop immunoassays for the detection of bryostatin 1 and its analogues in a variety of biological matrices. the bryostatins have exhibited strong antineoplastic activity in preclinical studies and are scheduled to enter phase i clinical trials later this… More

Neutralizing Monoclonal Antibodies to Maitotoxin

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$80,250.00
Agency:
HHS
Principal Investigator:
Gary Bignami
Abstract:
Murine monoclonal antibodies which neutralize maitotoxin will be selected using a functionalassay that exploits the hemolytic action of maitotoxin. The resulting antibodies should be useful forseveral purposes. They will provide a means to measure the toxin content in crude extracts of fishtissues… More

Yeast Ty-Dengue Fusion Particles for Vaccines

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$80,591.00
Agency:
HHS
Principal Investigator:
John Ivy
Abstract:
Dengue viruses are a leading cause of morbidity and mortality throughout the tropics andsubtropics. It is estimated that more than 100 million people in the tropics are infected annually by thisvirus. This threat has now reached the southern United States with the arrival of the Aedes… More

Microperoxidase-Antibody Conjugates for Toxin Biosensing

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Mark H. Smit, Phd
Abstract:
Several fundamental parameters need to be addressed with regard to the development of biosensors. Protein stability is a major criteria for sensors devoted to long-term monitoring. The enzyme label is typically the most unstable componenet in biosensors. Additional problems encountered with… More

Expression of Antibodies in Neurospora

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$66,474.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
John Marshall Ivy, Ph.d.
Abstract:
The filamentous fungi, owing to their ability to secrete high levels of proteins, are attractive organisms for the expression and secretion of heterologous proteins of commercial and medical value. Secretion is a key element in their attraction, for secretion enables proper folding and processing of… More

Expression of Dengue Viral Proteins in Drosophila Cells

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$69,935.00
Agency:
HHS
Principal Investigator:
John Ivy
Abstract:
N/a

Bobust Binding Proteins of Predetermined Specificity

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Iain Peters
Abstract:
We will develop a specific binding protein that has antibody-like diversity but is suitable for higexpression and use in extreme environments. Production of recombinant antibodies in E. coli providessource of active protein for antibody-based technologies, and the small size of the recombinant… More

Synthetic Receptor Libraries for Small Organic Molecules

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Paul Grothaus
Abstract:
We will develop high affinity, highly selective, synthetic receptors for small organic molecules. Achemistry approach will be used to produce an encoded, highly diverse, novel type of receptor librarconsists of three peptide arms symmetrically arranged about a rigid hydrophobic pocket. This… More

Phage Displayed Antibodies to C. botulinum toxin A

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Eileen T. Nakano
Abstract:
N/a

Handheld Capillary Immunosensor Devices

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$65,000.00
Agency:
NSF
Principal Investigator:
Mark Smit
Abstract:
N/a

Detection of Campylobacter in Foods

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Steven Ogata
Abstract:
N/a

Expression of Dengue Viral Proteins in Drosophila Cells

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$742,445.00
Agency:
HHS
Principal Investigator:
John Ivy
Abstract:
Dengue virus causes dengue fever, a debilitating illness marked by high fever, headache, muscleand joint pain, and rash. The more severe forms of the illness, dengue hemorrhagic fever and dengueshock syndrome, are life threatening and are a principal cause of hospitalization among children… More

Catalytic Antibodies Which Mimic Urease Activity

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Paul G. Grothaus, Ph.d
Abstract:
The department of Defense is currently engaged in extensive biosensor research and development efforts. A major goal of these efforts id the development of automated field-usable systems for the detection of a variety of analytes including toxins, infectious organisms, and chemical agents in either… More

Phage Displayed Antibodies to C. botulinum toxin A

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$597,887.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Eileen T. Nakano
Abstract:
The neurotoxins of Clostridium botulinum are the most lethal proteins known. The bacterium is ubiquitous, and thus rapid, reliable, sensitive, and cost-effective assays are needed to detect the toxin. Current immunoassays provide a rapid means to detect the neurotoxin. Their sensitivity, however,… More

Immunocapture/PCR Detection of Campylobacter

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Steven A. Ogata
Abstract:
Campylobacter jefjuni and Campylobacter coli are significant pathogens of humans. In the United States, the estimated annual incidence of the disease 1-2 million cases costing almost one billion dollars in health care costs and lost productivity. Currently, effective vaccines for do not exist;… More

TARGETED AMPHOTERICIN B PRODRUG FOR ANTIFUNGAL THERAPY

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

DEVELOPMENT OF CAMPYLOBACTER FLAGELLIN SUBUNIT VACCINE

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Detection of Campylobacter in Foods

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$632,616.00
Agency:
HHS
Principal Investigator:
Steven Ogata
Abstract:
To ensure safety, it is essential to monitor foods for microbial pathogens. Campylobacter jejuni ancoli are significant food-borne pathogens of humans. In the United States, the estimated annual inci2 million cases costing almost one billion dollars in health care cost and lost productivity.… More

Combinatorial Transition State Analog Inhibitor Library for Botulinum Toxin

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Dr. Paul G. Grothaus
Abstract:
Botulism is a debilitating and often fatal intoxication for which there is no approved pharmacological treatment. The intent of Phase I research is threefold. First, to demonstrate that a combinatorial strategy can be used to identify novel, peptide-based inhibitors of BoNT/A light chain activity.… More

STABLE SYNTHETIC PEROXIDASE FOR VERSATILE ASSAYS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$96,837.00
Agency:
HHS
Principal Investigator:
O'malley, sean
Abstract:
N/a

COMBINATORIAL CYCLODEPSIPEPTIDE LIBRARIES FROM DIDEMNINS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Grothaus, paul g
Abstract:
N/a

DEVICE FOR RAPID DETECTION OF DENGUE--SPECIFIC ANTIBODY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Bignami, gary s
Abstract:
N/a

Immunoassay for the Detection of Botulinum Toxin A

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$65,000.00
Agency:
USDA
Principal Investigator:
Nakano , Principal Investigator
Abstract:
N/a

EXPRESSION OF MALARIA MSP-1 P42 C-TERMINAL FRAGMENT

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Clements, David E
Abstract:
N/a

ANTIBODY LIKE BINDING POCKET ON A ROBUST FRAMEWORK

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Peters, Iain
Abstract:
N/a

COMBINATORIAL LIBRARIES BASED ON DOLASTATIN 10

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Grothaus, Paul G
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$799,005.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Oligonucleotide Ligand Assay for Campylobacter

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$65,000.00
Agency:
USDA
Principal Investigator:
Abstract:
N/a

Synthesis of Dimercapturic Acid-Protein Conjugates For Production of Immunological Regants

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$69,823.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Xianglong Zou PhD
Abstract:
N/a

NOVEL STRATEGY FOR BIOSUBSTRATE PROTEIN KINASE INHIBITOR

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$114,102.00
Agency:
HHS
Principal Investigator:
Paul G. Grothaus
Abstract:
Not Available Impact Technologies in cooperation with the Applied Research Laboratory (ARL) at Penn State University proposes the development and implementation of metric strategies and algorithms to impartially evaluate the performance and effectiveness of diagnostic and prognostic technologies.… More

EXPRESSION OF HEPATITIS C VIRUS STRUCTURAL PROTEINS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Eileen T. Nakano
Abstract:
Not Available The Air Force needs an autonomous service vehicle to inspect, repair, upgrade, or refuel future satellites configured for on-orbit servicing. Such a vehicle must be very low mass, with a high power output for electric propulsion. Conventional ion rockets or arcjets may not have the… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$152,678.00
Agency:
HHS
Principal Investigator:
Andre S. Bachmann
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Eileen T. Nakano
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$494,021.00
Agency:
HHS
Principal Investigator:
Eileen T. Nakano
Abstract:
N/a

Viability Assay for Foodborne Bacterial Pathogens

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$70,000.00
Agency:
USDA
Principal Investigator:
Abstract:
There are an estimated 76 million cases of foodborne illness in the United States annually, resulting in 325,000 hospitalizations and 5,000 deaths. The financial impact has been estimated at $35 billion. Bacterial pathogens account for 14 million of the total cases. To assure food safety, monitoring… More

Development of a MSP1-p42 Subunit Vaccine for Malaria

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
David E. Clements
Abstract:
DESCRIPTION (provided by the applicant): Malaria is a tropical parasitic disease that poses a significant health threat to much of the world. Each year, approximately 500 million people become infected and more than 2 million die. There is a great need to control the spread… More

Development of a MSP1-p42 Subunit Vaccine for Malaria

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$501,978.00
Agency:
HHS
Principal Investigator:
David E. Clements
Abstract:
DESCRIPTION (provided by the applicant): Malaria is a tropical parasitic disease that poses a significant health threat to much of the world. Each year, approximately 500 million people become infected and more than 2 million die. There is a great need to control the spread… More

TARGETED PRODRUGS OF 9-AMINOCAMPTOTHECIN

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$274,209.00
Agency:
HHS
Principal Investigator:
Sean Omalley
Abstract:
DESCRIPTION (Adapted from the application): The goal of this project is to produce a water-soluble anticancer prodrug and an antibody-enzyme conjugate for use in Antibody-Directed Enzyme Prodrug Therapy (ADEPT). The prodrug will be a derivative of 9-aminocamptothecin (9AC), a… More

OLIGONUCLEOTIDE LIGANDS FOR PESTICIDE DETECTION IN FOODS

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Steven A. Ogata
Abstract:
DESCRIPTION (applicant's abstract): The detection of pesticide residue in foods is a significant issue in food safety. Current analytical methods, however, involve complicated and expensive equipment that requires skilled operators and cannot be readily applied to field… More

Novel Strategy for HCV NS3 Inhibitor Discovery

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$240,174.00
Agency:
HHS
Principal Investigator:
Paul G. Grothaus
Abstract:
DESCRIPTION (provided by applicant): An estimated 150 million people world-wide are infected with the hepatitis C virus (HCV), a major cause of chronic liver disease. The nonstructural protein 3 (NS3) of HCV is a multi-functional enzyme in the replication cycle of the virus and… More

EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$175,002.00
Agency:
HHS
Principal Investigator:
David E. Clements
Abstract:
DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a tropical parasitic disease that is a significant health threat. Each year, approximately 500 million people become infected and 2 to 3 million die worldwide. There is a great need to control the spread of this… More

Anti-Flavivirus Immunotherapeutics

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$172,415.00
Agency:
HHS
Principal Investigator:
Eileen T. Nakano
Abstract:
DESCRIPTION (provided by the applicant): There are 100 million cases of dengue infection each year with 250,000 cases of the life-threatening Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHS/DSS). Treatment options are limited to symptoms management. Passive… More

INHIBITORS OF ANTHRAX LETHAL FACTOR METALLOPROTEINASE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$295,510.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This proposal outlines a novel approach towards the development of a therapeutic agent to treat anthrax infection by inhibiting the intracellular actions of lethal factor, the main virulence factor expressed in Bacillus anthracis infected organisms. While… More

EVALUATION OF IMMUNOGENICITY : MALARIA SUBUNIT VACCINE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$129,871.00
Agency:
HHS
Principal Investigator:
Abstract:
Malaria is a tropical parasitic disease that poses a significant health threat to much of the world. Each year, approximately 500 million become infected and more them 2 million die. There is great need to control the spread of the disease. One of the main focuses of malaria vaccine development has… More

SELECTIVE ACTIVATION OF ANTIFUNGAL PRODRUGS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$299,488.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): The proposed research will investigate the feasibility of utilizing inherent properties of the infection site as a means to activate antifungal prodrugs selectively. Prodrug derivatives of an antifungal agent will be prepared and tested for their susceptibility… More

Development of a Subunit Vaccine for West Nile

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$189,420.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): West Nile virus infection has become an emerging infectious disease in the United States. The virus infects birds, the natural reservoir of the virus, and is transmitted to humans by the bite of the Culex mosquito. The virus has been found in bird populations… More

Recombinant Subunit Vaccine/Prevention of West Nile Vir*

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$5,046,576.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): West Nile virus infection is an emerging infectious disease in the United States. The virus infects birds, which serve as the natural reservoir for the virus, in addition to humans and horses which are incidental hosts. It is an arthropod-borne virus, being… More

Recombinant Subunit Vaccine for Tick-Borne Encephalitis

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$422,170.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tick-borne encephalitis (TBE) is a neurological disease caused by Flaviviruses of the tick-borne encephalitis group and causes death in up to 60% of the individuals developing clinical symptoms. Survivors often show severe long-term neurological sequelae. In… More

Recombinant Subunit Protein for Flu Vaccine

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$979,908.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Current influenza vaccine production procedures (use of embryonated chicken eggs) inherently limit the amount of influenza vaccine that can be produced prior to each year's flu season. Most of the influenza vaccine sold is inactivated. Inactivation of the virus… More

Discovery of West Nile Virus Protease Inhibitors

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$999,975.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The strain of West Nile virus now endemic in the continental United States is more virulent than the virus originally isolated in Africa and is classified as a category B priority pathogen by the NIAID. In only six years, it has spread throughout the continental… More

Structure Based Design of Dengue Virus Fusion Inhibitors

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$797,650.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Over half of the world population is at risk for infection by dengue virus, a mosquito borne member of the Flavivirus family that consists of four distinct serotypes. Approximately 50 to 100 million infections occur annually resulting in an estimated 500,000… More

Optimization of Small Molecule Botulinum Neurotoxin Inhibitors

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$1,019,214.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Medicinal and computational chemistry methods will be used to optimize validated hit compounds found to inhibit botulinum neurotoxin. These inhibitors, discovered through in silico docking and confirmed with an in vitro fluorescence resonance energy transfer… More

Recombinant Subunit Vaccine For Tick-Borne Encephalitis

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,983,509.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tick-borne encephalitis (TBE) is a neurological disease caused by Flaviviruses of the tick-borne encephalitis group and causes death in up to 60% of the individuals developing clinical symptoms. Survivors often show se vere long-term neurological sequelae. In… More

Development of a Recombinant Subunit Vaccine for CCHF

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$530,899.00
Agency:
HHS
Principal Investigator:
David E. Clements – 808-486-5333
Abstract:
DESCRIPTION (provided by applicant): Emerging and reemerging infectious diseases continue to pose serious health threats world-wide. Consequently, the development of measures to mitigate the natural, as well as potential bioterrorist threats of these infectious diseases is an important endeavor. The… More